Lipocalin 2 Protein (LCN2) (AA 21-200, C-Term, His10)

Catalog No. ABIN2666723

This Recombinant Lipocalin 2 protein is expressed in HEK-293 Cells.

Quick Overview for Lipocalin 2 Protein (LCN2) (AA 21-200, C-Term, His10) (ABIN2666723)

Target: Lipocalin 2 (LCN2)

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: HEK-293 Cells

Application: Western Blotting (WB)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 21-200, His10, C-Term

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determine by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: BC50 ≥ 0.7 μM, by dose dependent binding of the protein (4 μM) with [ Fe3+(DHBA)3] complex.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for three months, or at -70°C for six months.

Target Details

Target: Lipocalin 2 (LCN2)

Alternative Name: NGAL

Background: NGAL, also known as lipocalin 2, LCN2, and siderocalin, is a small molecule composed of 178 amino acids. It belongs to the lipocalin superfamily of 20 structurally related secreted proteins. Members of the lipocalin family share a highly conserved fold with an eight stranded antiparallel β barrel, and act as a transporter, carrying small molecules to specific cells. NGAL occurs predominantly in a monomeric form, with a small percentage occurring as a dimer or trimer. It is a critical component of innate immunity because its ability to bind iron-siderophore complexes limits bacterial growth. Mouse NGAL is detected in lung, spleen, uterus, vagina and epididymis. In addition to its role in innate immunity, it is a promising biomarker for acute kidney injury that is beginning to be used in clinical practice in addition to research studies.

Molecular Weight: The 195 amino acid recombinant protein has a predicted molecular mass of approximately 23 kDa. The DTT-reduced and non-reduced protein migrate at approximately 26-29 and 25-28 kDa by SDS-PAGE respectively. The N-terminal amino acid is blocked.

Pathways: Cellular Response to Molecule of Bacterial Origin, Transition Metal Ion Homeostasis